Navigation Links
MEI Pharma's Mitochondrial Inhibitor Drug Candidate ME-344 Named One of Top 10 Oncology Products for 2012
Date:11/19/2012

SAN DIEGO, Nov. 19, 2012 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that its lead mitochondrial inhibitor drug candidate, ME-344, has been named one of the Top 10 Most Licensable Oncology Products to Watch for 2012 by Elsevier Business Intelligence and Campbell Alliance.

(Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

"We are honored to have ME-344 considered among the most attractive oncology opportunities in the industry," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "We believe ME-344 is a novel compound with a unique mechanism of action that has the potential to complement standards-of-care and significantly improve treatment outcomes for patients with cancer. Our Phase I clinical trial of ME-344 in patients with solid refractory tumors is nearing completion of enrollment and we look forward to reporting its results, along with our plans for its next phase of clinical development, during the second quarter of 2013."

Projects were selected using a set of judging criteria that included unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. Selected projects will be presented at the Windhover Therapeutic Area Partnerships conference in Boston on November 29, 2012. More information can be found at www.tapartnerships.com.

About ME-344

ME-344 is MEI Pharma's lead mitochondrial inhibitor and an active metabolite of NV-128, its first-generation compound. In April 2011, Ayesha Alvero, M.D., Department of Obstetri
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
5. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
6. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
7. Global Markets for Enzyme Inhibitors
8. Global Angiogenesis Inhibitors and Stimulators Industry
9. Kinase Inhibitors Market to Reach $11.6 Billion in US, $40.3 Billion Globally by 2016
10. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
11. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today announced ... shares of its common stock at a price to ... to Tandem from this offering are expected to be ... other estimated offering expenses payable by Tandem. All of ...
(Date:2/26/2015)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced that ... financial results after the market closes on Thursday, March ... will host a conference call with the investment community at ... 5, 2015 to discuss the results of the quarter ... the live conference call via telephone by dialing (877) 407-0784 ...
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015 Legislation ... includes a pharmacy provision to help prevent inappropriate prescriptions ... The Protecting the Integrity of Medicare Act (PIMA) ... Subcommittee Chairman Kevin Brady (R-TX) and Ranking ... the prescription drug abuse epidemic and implement the right ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2
... study released on September 20, 2010, in the ... innovation in post-op treatment for facelifts.  The study, performed ... Dr. Andrew Jacono details how Hyperbaric Oxygen (HBO) Therapy ... decrease bruising by 35 percent, seven days post-operation.   ...
... Germany, September 21, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
Cached Medicine Technology:Facelift Healing Innovation: New Study Shows Hyperbaric Oxygen Therapy Decreases Bruising in Facelifts Patients by 35% 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10
(Date:3/1/2015)... 01, 2015 ERISAPros is ... Carolyn Roddy to the professional staff of its Compliance ... from The Ohio State University-Mortiz College of Law. Prior ... experience working with several Fortune 500 companies as well ... of corporate benefits. Her experiences range from benefit plan ...
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people ... innovative thinking. “The #1 block was lack of ... reports Haman, who created the Thinkubator Innovation Studio in ... that they did not have enough time for innovative ... stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops ...
(Date:2/28/2015)... 28, 2015 March—also known as ... to remind ourselves and others that suspected head ... NeuroSurgical Specialists (ANS). , Concussions are a form ... 75% of TBIs. There are 1.6-3.8 million sports-related ... benign, but it is a brain injury. Many ...
(Date:2/28/2015)... A study out of the University ... procedure for the treatment of a hereditary ocular condition ... Authored by Dr. Robert MacLaren, professor of ophthalmology at ... Medical Journal on January 16, 2014 , the study ... disorder that mostly affects men and leads to the ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... is EBCC? , The most exciting breast cancer conference ... all the major players in breast cancer. The conference ... in a partnership of equals to talk not just ... and practical issues associated with caring for patients with ...
... and the,Aronson Foundation, a charitable organization, recently presented a ... The gift,raised from and by Aronson & Company staffers, ... the young patients., Commented Lisa J. Cines, Managing ... further support the hospital in their efforts to help,the ...
... 9 Percent to $12.4 Billion, ARLINGTON HEIGHTS, ... and a looming home lending crisis, average,Americans continue ... the,latest procedural statistics report from the American Society ... surgery procedures were,performed in 2007 - a 7 ...
... Scot Rourke, President and CEO of,OneCommunity, has been ... 2008 by the Intelligent Community Forum (ICF), (http://www.intelligentcommunity.org ... to,studying economic growth in the Broadband Economy., ... in Cleveland, Ohio today.,Rourke will make the Intelligent ...
... Survey Shows Increasing Use of Tiered Copayments, Generics, ... WASHINGTON, March 25 A new survey of,employers ... tools,has helped to slow the cost of prescription ... manager (PBM) tools in increasing savings,and access for ...
... This release is available in German . , , ... these common figures of speech can be taken literally, ... of us would like. For it turns out that intense ... and increase the risk of thrombosis or heart attack. , ...
Cached Medicine News:Health News:An invitation to Europe's largest forum on breast cancer 2Health News:The Aronson Foundation Makes Charitable Donation to Children's Hospital 2Health News:Plastic Surgery Procedures Maintain Steady Growth in 2007 2Health News:OneCommunity's Scot Rourke Named Intelligent Community Visionary of the Year for 2008 2Health News:Employers: Proven PBM Tools Slowing Cost of Prescription Drug Benefits 2Health News:Fear that freezes the blood in your veins 2Health News:Fear that freezes the blood in your veins 3
... FlexiGel Strands® Absorbent Wound Dressing is a ... use in moist wound dressing applications. The ... conform to the wound contours, and entraps slough ... in debridement. The strands of the matrix ...
... IMD offers for purchase a comprehensive ... IMD highly recommends the implementation of ... the facility's clinical, financial and patient ... data provides the benefit of streamlined ...
Features various cylinder sizes and a simple two-handed pumping mechanism....
... Special Peristaltic phacoemulsification system features microprocessor control ... programmability and remote control for all settings. ... panel with color coded function modes and ... of use and viewing. Under control of ...
Medicine Products: